The pharmaceutical company Boehringer Ingelheim closed 2022 with an investment of 46.1 million euros in R&D projects at the Sant Cugat del Vallès headquarters. According to the German multinational, this deployment of resources, 8.6% higher than the previous year, has helped 1.1 million patients in the State.

"Our goal is to improve the lives of people and animals, especially in areas with unmet needs," describes Peter Ploeger. The general manager and head of the Boehringer Human Health division in Spain assures that "the latest results position us as a key player in the national healthcare ecosystem."

Currently, at the headquarters in Sant Cugat del Vallés, the pharmaceutical company outlines its future scenarios with three international hubs (IT Hub, Delivery Unit and Regulatory Affairs). "Our competitiveness and profitability are the basis for discovering innovative new therapies," says Torsten Eschenbrenner, Boehringer's CFO. Today these facilities welcome a total of 1,600 workers of 41 nationalities.